Photodynamic Therapy of Multiple Nonmelanoma Skin Cancers with Verteporfin and Red Light-Emitting Diodes Two-Year Results Evaluating Tumor Response and Cosmetic Outcomes

Archives of Dermatology

Volumn 140, Issue 1, 2004, Pages 26-32

  Lui, Harvey ^a,b   Hobbs, Lori ^c   Tope, Whitney D ^a   Lee, Peter K ^c   Elmets, Craig ^c   Provost, Nathalie ^c   Chan, Agnes ^a   Neyndorff, Herma ^a   Yao Su, Xiang ^a   Jain, Hem ^c   Hamzavi, Iltefat ^a   McLean, David ^a   Bissonnette, Robert ^a  

^a QLT Inc   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

ADULT; AGED; ARTICLE; BURNING SENSATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EDEMA; ERYTHEMA; EXUDATE; FEMALE; FOLLOW UP; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERESTHESIA; HYPERTROPHY; LIGHT EMITTING DIODE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PHOTODYNAMIC THERAPY; PHOTOPHOBIA; PHOTOSENSITIZATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RED LIGHT; SAFETY; SKIN BIOPSY; SKIN CARCINOMA; SKIN TINGLING; SQUAMOUS CELL CARCINOMA; SUPERFICIAL CANCER; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BOWEN'S DISEASE; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; SKIN NEOPLASMS;

EID: 9144272242     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.140.1.26     Document Type: Article

References (27)

1. American Cancer Society. What are the key statistics for nonmelanoma skin cancer? Available at: http://www.cancer.org/docroot/cri/content /cri_2_4_1x_what_are_the_key_statistics_for_skin_cancer_51.asp ?sitearea=cri. Accessed September 15, 2003.
2. Friedman RJ, Rigel DS, Nossa R, Dorf R. Basal cell and squamous cell carcinoma of the skin. In: Murphy GP, Lawrence W, Lenhard RE, eds. American Cancer Society Textbook of Clinical Dncology. 2nd ed. Washington, DC: American Cancer Society; 1995:330-341.
3. Bissonnette R, Lui H. Current status of photodynamic therapy in dermatology. Dermatol Clin. 1997;15:507-519.
4. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
5. Lipsitz SR, Kim K. Analysis of repeated categorical data using generalized estimating equations. Stat Med. 1994;13:1149-1163.
6. Fisher LD, van Belle G. Biostatistics: A Methodology for the Health Sciences. New York, NY: John Wiley & Sons Inc; 1993:950.
7. Keller GS, Razum NJ, Doiron DR. Photodynamic therapy for nonmelanoma skin cancer. Facial Plast Surg. 1989;6:180-184.
8. Wilson BD, Mang TS, Stoll H, Jones C, Cooper M, Dougherty TJ. Photodynamic therapy for the treatment of basal cell carcinoma [see comments]. Arch Dermatol. 1992;128:1597-1601.
9. Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A. Photoradiation therapy for the treatment of malignant tumors. Cancer Res. 1978; 38:2628-2635.
10. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B. 1990;6:143-148.
11. Sommer CA, van Leengoed H, Conti CM, et al. Photodynamic therapy (PDT) for cutaneous carcinomas using the second generation photosensitizer tin ethyl etiopurpurin (SnET2). Lasers Surg Med. 1995;suppl 7:45.
12. Dilkes MG, DeJode ML, Rowntree-Taylor A, McGilligan JA, Kenyon GS, McKelvie P. M-THPS photodynamic therapy for head and neck cancer. Lasers Med Sci. 1996;11:23-29.
13. Wooten RS, Smith KC, Ahlquist DA, Muller SA, Balm RK. Prospective study of cutaneous phototoxicity after systemic hematoporphyrin derivative. Lasers Surg Med. 1988;8:294-300.
14. Svanberg K, Andersson T, Killander D, et al. Photodynamic therapy of nonmelanoma malignant tumours of the skin using topical delta-amino levulinic acid sensitization and laser irradiation. Br J Dermatol. 1994;130:743-751.
15. Wolf P, Rieger E, Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid: an alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas [published erratum appears in J Am Acad Dermatol. 1993;29: 41]? J Am Acad Dermatol. 1993;28:17-21.
16. Wolf P, Rieger E, Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid: an alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas [published erratum appears in J Am Acad Dermatol. 1993;29: 41]? J Am Acad Dermatol. 1993;28:17-21.
17. Cairnduff F, Stringer MR, Hudson EJ, Ash DV, Brown SB. Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. Br J Cancer. 1994;69:605-608.
18. Calzavara-Pinton PG. Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial nonmelanoma skin tumours. J Photochem Photobiol B. 1995;29:53-57.
19. Fijan S, Honigsmann H, Ortel B. Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine. Br J Dermatol. 1995; 133:282-288.
20. Wennberg AM, Lindholm LE, Alpsten M, Larko O. Treatment of superficial basal cell carcinomas using topically applied delta-aminolaevulinic acid and a filtered xenon lamp. Arch Dermatol Res. 1996;288:561-564.
21. Thissen MR, Schroeter CA, Neumann HA. Photodynamic therapy with delta-aminolaevulinic acid for nodular basal cell carcinomas using a prior debulking technique. Br J Dermatol. 2000;142:338-339.
22. Martin A, Tope WD, Grevelink JM, et al. Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment. Arch Dermatol Res. 1995; 287:665-674.
23. Bassel-Seguin N, Ibbotson S, Emtestam L, et al. Photodynamic therapy using Metvix is as efficacious as cryotherapy in BCC, with better cosmetic results. J Eur Acad Dermatol Venereol. 2001;15(suppl 2):226-227.
24. Wennberg AM, Horn M, Wulf HC, et al. Metvix photodynamic therapy in patients with basal cell carcinoma at risk of complications and poor cosmetic outcome after conventional therapy. J Eur Acad Dermatol Venereol. 2001;15 (suppl 2):227.
25. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol. 2000;45:195-214.
26. Granville DJ, Carthy CM, Jiang H, Shore GC, McManus BM, Hunt DW. Rapid cytochrome c release, activation of caspases 3, 6, 7 and 8 followed by Bap31 cleavage in HeLa cells treated with photodynamic therapy. FEBS Lett. 1998;437: 5-10.
27. Tsoukas MM, Gonzalez S, Flotte TJ, Anderson RR, Sherwood ME, Kollias N. Wavelength and fluence effect on vascular damage with photodynamic therapy on skin. J Invest Dermatol. 2000;114:303-308.